

# Giannis Mountzios

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11900086/publications.pdf>

Version: 2024-02-01

35  
papers

1,164  
citations

304743

22  
h-index

395702

33  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2383  
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2016, 8, 479-488.	2.0	136
2	Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor- $\kappa$ B ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. <i>Acta Oncologica</i> , 2007, 46, 221-229.	1.8	83
3	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
4	ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2007, 13, 284-289.	2.6	79
5	The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality. <i>Cancer Treatment Reviews</i> , 2018, 67, 34-44.	7.7	71
6	Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 598-604.	7.7	46
7	All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. <i>Cancer Treatment Reviews</i> , 2011, 37, 221-233.	7.7	45
8	Immunotherapy and lung cancer: current developments and novel targeted therapies. <i>Immunotherapy</i> , 2014, 6, 1221-1235.	2.0	44
9	Novel chemotherapy regimens for advanced lung cancer: have we reached a plateau?. <i>Annals of Translational Medicine</i> , 2018, 6, 139-139.	1.7	44
10	Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression and Survival in Operable Squamous-Cell Laryngeal Cancer. <i>PLoS ONE</i> , 2013, 8, e54048.	2.5	39
11	Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 75, 94-109.	4.4	38
12	Prognostic Significance of Bone Markers in Patients With Lung Cancer Metastatic to the Skeleton: A Review of Published Data. <i>Clinical Lung Cancer</i> , 2011, 12, 341-349.	2.6	35
13	Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group. <i>Lung Cancer</i> , 2012, 77, 146-150.	2.0	34
14	Developments in the systemic treatment of metastatic cervical cancer. <i>Cancer Treatment Reviews</i> , 2013, 39, 430-443.	7.7	34
15	A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. <i>Immunotherapy</i> , 2016, 8, 1011-1019.	2.0	34
16	Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the bisphosphonate zoledronic acid. <i>Translational Research</i> , 2010, 155, 247-255.	5.0	29
17	Developments in the systemic treatment of endometrial cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 79, 278-292.	4.4	29
18	Future perspectives in cancer immunotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 273-273.	1.7	29

#	ARTICLE	IF	CITATIONS
19	The emerging treatment landscape of advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 138-138.	1.7	29
20	Optimal management of the elderly patient with head and neck cancer: Issues regarding surgery, irradiation and chemotherapy. <i>World Journal of Clinical Oncology</i> , 2015, 6, 7.	2.3	28
21	Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy. <i>Translational Lung Cancer Research</i> , 2016, 5, 588-598.	2.8	28
22	Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2018, 6, 142-142.	1.7	27
23	Mechanisms of Disease: signal transduction in lung carcinogenesis—a comparison of smokers and never-smokers. <i>Nature Clinical Practice Oncology</i> , 2008, 5, 610-618.	4.3	22
24	Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes. <i>PLoS ONE</i> , 2014, 9, e91407.	2.5	15
25	Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 4185-4190.	1.1	13
26	Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemia. <i>Molecular and Clinical Oncology</i> , 2016, 4, 211-220.	1.0	11
27	Novel therapies for advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2016, 12, 659-667.	2.4	11
28	A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer. <i>Drug Safety</i> , 2011, 34, 175-186.	3.2	9
29	Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis. <i>Oncotarget</i> , 2018, 9, 11805-11815.	1.8	9
30	Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece. <i>Journal of Geriatric Oncology</i> , 2015, 6, 111-118.	1.0	8
31	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016, 12, 551-564.	2.4	8
32	Genotyping <i>KRAS</i> and <i>EGFR</i> Mutations in Greek Patients With Non-small-cell Lung Cancer: Incidence, Significance and Implications for Treatment. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 531-541.	2.0	8
33	Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non-Platinum-Containing Regimens, and Molecular Targeted Agents. <i>Obstetrics and Gynecology International</i> , 2013, 2013, 1-8.	1.3	7
34	The Case of the Missed Chest Radiograph: Bilateral Mammary Gland Metastases Mimicking Multifocal Primary Breast Cancer as the Initial Manifestation of Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1729-1731.	1.1	0
35	Adjuvant bevacizumab for resected non-small cell lung cancer: the end of an era?. <i>Translational Lung Cancer Research</i> , 2018, 7, S179-S182.	2.8	0